Hellen Kuasne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12074640/publications.pdf Version: 2024-02-01



HELLEN KUASNE

#	Article	IF	CITATIONS
1	Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair. NAR Cancer, 2022, 4, zcac013.	3.1	5
2	Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies. Cells, 2021, 10, 814.	4.1	9
3	Circulating mRNA signature as a marker for high-risk prostate cancer. Carcinogenesis, 2020, 41, 139-145.	2.8	12
4	CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. Cancer Research, 2020, 80, 444-457.	0.9	88
5	GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nature Communications, 2020, 11, 4205.	12.8	130
6	Epigenetic Switch–Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. Cancer Discovery, 2020, 10, 1312-1329.	9.4	84
7	DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions. Thyroid, 2019, 29, 1244-1254.	4.5	19
8	E-Cadherin Downregulation is Mediated by Promoter Methylation in Canine Prostate Cancer. Frontiers in Genetics, 2019, 10, 1242.	2.3	6
9	Deregulation of E-cadherin, β-catenin, APC and Caveolin-1 expression occurs in canine prostate cancer and metastatic processes. Research in Veterinary Science, 2018, 118, 254-261.	1.9	20
10	Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma. Clinical Epigenetics, 2018, 10, 144.	4.1	27
11	<scp>SHLD</scp> 2/ <scp>FAM</scp> 35A coâ€operates with <scp>REV</scp> 7 to coordinate <scp>DNA</scp> doubleâ€strand break repair pathway choice. EMBO Journal, 2018, 37, .	7.8	111
12	Nuclear loss and cytoplasmic expression of androgen receptor in penile carcinomas: role as a driver event and as a prognosis factor. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 607-614.	2.8	7
13	Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas. Clinical Epigenetics, 2017, 9, 45.	4.1	68
14	Multidimensional integrative analysis uncovers driver candidates and biomarkers in penile carcinoma. Scientific Reports, 2017, 7, 6707.	3.3	35
15	Prognostic Classifier Based on Genome-Wide DNA Methylation Profiling in Well-Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4089-4099.	3.6	45
16	Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. PLoS ONE, 2017, 12, e0184094.	2.5	95
17	Integrative miRNA and mRNA analysis in penile carcinomas reveals markers and pathways with potential clinical impact. Oncotarget, 2017, 8, 15294-15306.	1.8	39
18	A comprehensive characterization of cell cultures and xenografts derived from a human verrucous penile carcinoma. Tumor Biology, 2016, 37, 11375-11384.	1.8	16

Hellen Kuasne

#	Article	IF	CITATIONS
19	Genomic Profiling of Human Penile Carcinoma Predicts Worse Prognosis and Survival. Cancer Prevention Research, 2015, 8, 149-156.	1.5	52
20	Genome-wide methylation and transcriptome analysis in penile carcinoma: uncovering new molecular markers. Clinical Epigenetics, 2015, 7, 46.	4.1	48
21	Epigenetic Mechanisms in Penile Carcinoma. International Journal of Molecular Sciences, 2013, 14, 10791-10808.	4.1	17
22	Evaluation of the influence of polymorphic variants CYP1A1*2B, CYP1B1*2, CYP3A4*1B, GSTM1*0, and GSTT1*0 in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 654-663.	1.6	28
23	Polymorphisms in theARandPSAGenes as Markers of Susceptibility and Aggressiveness in Prostate Cancer. Cancer Investigation, 2010, 28, 917-924.	1.3	8
24	Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clinical and Experimental Medicine, 2009, 9, 21-28.	3.6	47
25	Interplay Between Immune and Cancer-Associated Fibroblasts: A Path to Target Metalloproteinases in Penile Cancer. Frontiers in Oncology, 0, 12, .	2.8	2